<p>泰爾茂（TSE:4543）剛剛獲得 FDA 510(k) 批准，推出其 OPUSWAVE 雙傳感器成像系統，包括 DualView 成像導管。這一發布標誌着泰爾茂進入美國心血管成像市場，採用 OFDI 和 IVUS 雙重方法。</p>
<p>查看我們對泰爾茂的最新分析。</p>
<p>泰爾茂的新 FDA 批准為其穩步推出產品和臨牀合作伙伴關係的一年增添了動力。然而，股價的動能依然疲軟，過去一年總股東回報為-10.3%，年初至今股價回報為-14.6%。儘管面臨這些近期挑戰，長期持有者在五年內仍獲得了 38.5% 的總股東回報。這表明公司的創新仍然為投資者提供了價值。</p>
<p>如果泰爾茂的突破讓你想到更大的機會，這可能是通過我們精心挑選的醫療創新者名單尋找機會的完美時刻：免費查看完整名單。</p>
<p>隨着新產品的突破和與分析師目標價格的顯著折扣，投資者現在面臨一個經典的困境：泰爾茂目前被低估，還是這些催化劑已經反映在股價中？</p>
<h2>最受歡迎的敍述：22.1% 被低估</h2>
<p>敍述共識認為泰爾茂的公允價值顯著高於其最後收盤價，突顯了當前市場情緒與預期財務實力之間的脱節。以下來自敍述的見解提供了分析師認為可能推動下一輪上漲的窗口。</p>
<blockquote>
<p><em>定價舉措，特別是在心血管和神經血管領域，比預期更為有效。價格上漲已嵌入合同中，預計通過合同續簽將進一步改善價格。這支持了更高的毛利率和營業利潤率，儘管預計關税將帶來壓力。</em></p>
</blockquote>
<p>閲讀完整敍述。</p>
<p>想知道這種看漲前景背後的數字嗎？秘密在於分析師對利潤率擴張和頂線增長的預期，幾乎沒有競爭對手能夠匹敵。想了解推動當前價格與目標價值之間如此大差距的假設嗎？解鎖這一潛在關鍵升級背後的完整推理。</p>
<p><strong>結果：公允價值為¥3,288.57（被低估）</strong></p>
<p>完整閲讀敍述，瞭解預測背後的原因。</p>
<p>然而，持續的關税影響和創新投資放緩可能成為挑戰，影響泰爾茂盈利軌跡的樂觀前景。</p>
<p>瞭解這一泰爾茂敍述的關鍵風險。</p>
<h2>另一種觀點：倍數暗示了什麼？</h2>
<p>從比較的角度來看，泰爾茂的市盈率為 30.2 倍，顯著高於行業平均的 15.5 倍和直接競爭對手的 22.1 倍。這使得該股票在大多數競爭對手中顯得昂貴。其公允比率為 31.2 倍，表明市場可能會為其定價溢價。這一溢價是否反映了真正的機會，還是可能在預期變化時使投資者面臨下行風險？</p>
<p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b0fc3ba8-0335-475f-b9bf-c0cda7d8cf15/chart/pe-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b0fc3ba8-0335-475f-b9bf-c0cda7d8cf15/chart/pe-multiple-vs-industry"/></p>
<p>截至 2025 年 10 月的 TSE:4543 市盈率</p>
<h2>構建你自己的泰爾茂敍述</h2>
<p>如果這個觀點與你的看法不符，或者你想得出自己的結論，你可以在幾分鐘內輕鬆構建個人敍述。按照你的方式進行。</p>
<p>一個好的起點是我們的分析，強調投資者對泰爾茂的四個關鍵回報的樂觀預期。</p>
<h2>尋找更多投資想法？</h2>
<p>聰明的投資者從不滿足於僅僅一個機會。通過鎖定具有動態基本面和潛在卓越回報的股票，領先於人羣。</p>
<ul>
<li>通過這些 28 只量子計算股票捕捉與未來技術相關的高收益機會。</li>
<li>通過這些 17 只收益率超過 3% 的分紅股票確保穩定的收入流，這些股票具有可靠的支付者和吸引人的收益率。</li>
<li>發現被低估的珍品，並通過這些 873 只基於現金流的被低估股票提前佈局，基於真實的現金流分析和價值信號。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也不考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

泰爾茂(ADR)

<p>泰爾茂（TSE:4543）已獲得 FDA 批准其 OPUSWAVE 雙傳感器成像系統，標誌着其進入美國心血管成像市場。儘管近期推出了新產品，但公司的股價仍然下跌，過去一年總股東回報率為-10.3%。分析師認為泰爾茂被低估，公允價值為¥3,288.57，得益於有效的定價策略。然而，其市盈率為 30.2 倍，高於行業平均水平，這引發了對潛在下行風險的擔憂。投資者被鼓勵進一步探索醫療創新領域的機會</p>

<p>Terumo (TSE:4543) just earned FDA 510(k) clearance for its OPUSWAVE Dual Sensor Imaging System, including the DualView imaging catheter. This launch marks Terumo’s entry into US cardiovascular imaging with an OFDI and IVUS dual approach.</p>
<div class="lb-trans"><p>泰爾茂（TSE:4543）剛剛獲得 FDA 510(k) 批准，推出其 OPUSWAVE 雙傳感器成像系統，包括 DualView 成像導管。這一發布標誌着泰爾茂進入美國心血管成像市場，採用 OFDI 和 IVUS 雙重方法。</p>
</div><p>See our latest analysis for Terumo.</p>
<div class="lb-trans"><p>查看我們對泰爾茂的最新分析。</p>
</div><p>Terumo’s new FDA clearance adds to a year of steady product launches and clinical partnerships. However, momentum in the share price has remained muted, with a 1-year total shareholder return of -10.3% and a year-to-date share price return of -14.6%. Despite these recent headwinds, long-term holders have still benefited from a 38.5% total shareholder return over five years. This suggests the company’s innovation continues to offer value for patient investors.</p>
<div class="lb-trans"><p>泰爾茂的新 FDA 批准為其穩步推出產品和臨牀合作伙伴關係的一年增添了動力。然而，股價的動能依然疲軟，過去一年總股東回報為-10.3%，年初至今股價回報為-14.6%。儘管面臨這些近期挑戰，長期持有者在五年內仍獲得了 38.5% 的總股東回報。這表明公司的創新仍然為投資者提供了價值。</p>
</div><p>If Terumo’s breakthrough has you thinking bigger, this might be the perfect moment to seek out healthcare innovators through our curated list: See the full list for free.</p>
<div class="lb-trans"><p>如果泰爾茂的突破讓你想到更大的機會，這可能是通過我們精心挑選的醫療創新者名單尋找機會的完美時刻：免費查看完整名單。</p>
</div><p>With fresh product breakthroughs and a sizable discount to analyst price targets, investors now face a classic dilemma: is Terumo currently undervalued, or are these catalysts all baked into the share price already?</p>
<div class="lb-trans"><p>隨着新產品的突破和與分析師目標價格的顯著折扣，投資者現在面臨一個經典的困境：泰爾茂目前被低估，還是這些催化劑已經反映在股價中？</p>
</div><h2>Most Popular Narrative: 22.1% Undervalued</h2>
<div class="lb-trans"><h2>最受歡迎的敍述：22.1% 被低估</h2>
</div><p>The narrative consensus sees Terumo's fair value significantly above its last close, highlighting the disconnect between current market sentiment and projected financial strength. The following insight from the narrative provides a window into what analysts believe could power the next leg up.</p>
<div class="lb-trans"><p>敍述共識認為泰爾茂的公允價值顯著高於其最後收盤價，突顯了當前市場情緒與預期財務實力之間的脱節。以下來自敍述的見解提供了分析師認為可能推動下一輪上漲的窗口。</p>
</div><blockquote>
<p><em>Pricing initiatives, particularly in the Cardiovascular and Neurovascular segments, have been more effective than anticipated. Price increases are being embedded into contracts, and further price improvements are expected through contract renewals. This is supporting higher gross and operating margins despite expected headwinds from tariffs.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>定價舉措，特別是在心血管和神經血管領域，比預期更為有效。價格上漲已嵌入合同中，預計通過合同續簽將進一步改善價格。這支持了更高的毛利率和營業利潤率，儘管預計關税將帶來壓力。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>閲讀完整敍述。</p>
</div><p>Want to know the numbers behind this bullish outlook? The secret lies in analyst expectations for margin expansion and top-line growth few competitors can match. Curious about the assumptions driving such a large gap between current price and target value? Unlock the full reasoning behind this potentially pivotal upgrade.</p>
<div class="lb-trans"><p>想知道這種看漲前景背後的數字嗎？秘密在於分析師對利潤率擴張和頂線增長的預期，幾乎沒有競爭對手能夠匹敵。想了解推動當前價格與目標價值之間如此大差距的假設嗎？解鎖這一潛在關鍵升級背後的完整推理。</p>
</div><p><strong>Result: Fair Value of ¥3,288.57 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>結果：公允價值為¥3,288.57（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整閲讀敍述，瞭解預測背後的原因。</p>
</div><p>However, ongoing tariff impacts and slower innovation investment could become headwinds and challenge the upbeat outlook for Terumo's earnings trajectory.</p>
<div class="lb-trans"><p>然而，持續的關税影響和創新投資放緩可能成為挑戰，影響泰爾茂盈利軌跡的樂觀前景。</p>
</div><p>Find out about the key risks to this Terumo narrative.</p>
<div class="lb-trans"><p>瞭解這一泰爾茂敍述的關鍵風險。</p>
</div><h2>Another View: What Do Multiples Suggest?</h2>
<div class="lb-trans"><h2>另一種觀點：倍數暗示了什麼？</h2>
</div><p>Looking through a comparative lens, Terumo’s price-to-earnings ratio stands at 30.2x, which is significantly higher than both the industry average of 15.5x and direct peers at 22.1x. This makes the stock look expensive versus most competitors. Its fair ratio of 31.2x suggests the market might justify a premium. Does this premium reflect genuine opportunity, or could it expose investors to downside if expectations shift?</p>
<div class="lb-trans"><p>從比較的角度來看，泰爾茂的市盈率為 30.2 倍，顯著高於行業平均的 15.5 倍和直接競爭對手的 22.1 倍。這使得該股票在大多數競爭對手中顯得昂貴。其公允比率為 31.2 倍，表明市場可能會為其定價溢價。這一溢價是否反映了真正的機會，還是可能在預期變化時使投資者面臨下行風險？</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b0fc3ba8-0335-475f-b9bf-c0cda7d8cf15/chart/pe-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/b0fc3ba8-0335-475f-b9bf-c0cda7d8cf15/chart/pe-multiple-vs-industry"/></p>
<p>TSE:4543 PE Ratio as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 TSE:4543 市盈率</p>
</div><h2>Build Your Own Terumo Narrative</h2>
<div class="lb-trans"><h2>構建你自己的泰爾茂敍述</h2>
</div><p>If this perspective does not resonate with you, or you want to draw your own conclusions, you can easily craft a personal narrative in just a few minutes. Do it your way</p>
<div class="lb-trans"><p>如果這個觀點與你的看法不符，或者你想得出自己的結論，你可以在幾分鐘內輕鬆構建個人敍述。按照你的方式進行。</p>
</div><p>A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Terumo.</p>
<div class="lb-trans"><p>一個好的起點是我們的分析，強調投資者對泰爾茂的四個關鍵回報的樂觀預期。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>尋找更多投資想法？</h2>
</div><p>Smart investors never settle for just one opportunity. Jump ahead of the crowd by pinpointing stocks with dynamic fundamentals and the potential for outstanding returns.</p>
<div class="lb-trans"><p>聰明的投資者從不滿足於僅僅一個機會。通過鎖定具有動態基本面和潛在卓越回報的股票，領先於人羣。</p>
</div><ul>
<li>Capture growth by targeting high-yielding opportunities linked to future technologies with these 28 quantum computing stocks.</li>
<li>Secure steady income streams by tapping into these 17 dividend stocks with yields &gt; 3%, which features reliable payers with attractive yields above 3%.</li>
<li>Uncover underappreciated gems and get a head start with these 873 undervalued stocks based on cash flows, based on real cash flow analysis and value signals.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過這些 28 只量子計算股票捕捉與未來技術相關的高收益機會。</li>
<li>通過這些 17 只收益率超過 3% 的分紅股票確保穩定的收入流，這些股票具有可靠的支付者和吸引人的收益率。</li>
<li>發現被低估的珍品，並通過這些 873 只基於現金流的被低估股票提前佈局，基於真實的現金流分析和價值信號。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也不考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

泰爾茂（TSE:4543）在獲得 FDA 批准後，其在美國心血管成像領域的首次亮相引發了對其估值的關注